PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
|Articles|January 2, 2017
- Pharmaceutical Technology-01-02-2017
- Volume 41
- Issue 1
Vials Reduce Risk of Drug Container Interactions
The DualFUSION vials from Wheaton for the storage of lyophilized materials are engineered using a plasma enhanced chemical vapor deposition technology to fuse an organosilicate protective layer with silica-like barrier layer, and then fuses that inner material to a cyclic olefin polymer outer shell.
The DualFUSION vials from Wheaton for the storage of lyophilized materials are engineered using a plasma enhanced chemical vapor deposition technology to fuse an organosilicate protective layer with silica-like barrier layer, and then fuses that inner material to a cyclic olefin polymer outer shell. The inert silica-like barrier layer of the vial is impermeable to oxygen and other gases from the surrounding environment, and protects against delamination and leaching of contaminants, reducing the risk of drug-container interactions. The protection provided by the innovation composition and construction of DualFUSION vials minimizes caking that can occur in lyophilized drug products.
DualFUSION vials can withstand a temperature range of -196 oC to 121 oC without cracking. A unique 2D barcode laser etched onto the bottom of each DualFUSION vial facilitates sample identification and product lot traceability. The vials can be used in the manufacture of proteins, peptides, enzymes, DNA, and RNA--of complex formulations that may be sensitive to oxygen or metal ion exposure--and of highly potent and radioactive substances.
Articles in this issue
almost 10 years ago
Predicting Moisture Uptake in Solid Dosage Packagingalmost 10 years ago
Blister Packaging Moves Forwardalmost 10 years ago
Staffing and Preparation for Auditsalmost 10 years ago
Automatic Purge System for Control Panelsalmost 10 years ago
Fully Automated Capping Systemsalmost 10 years ago
Spray Dryer for Efficient Microencapsulationalmost 10 years ago
The Tide Stays Highalmost 10 years ago
Drug Quality Key to Innovation and Accessalmost 10 years ago
FDA New Drug Approvals Down Significantly in 2016almost 10 years ago
Beyond Distractions, Pharma Moves OnRelated to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.